(Q38543069)

English

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report

scientific article published on 06 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report (English)

1 reference

Europe PubMed Central

4 September 2017

0 references

cystic fibrosis

0 references

8

0 references

author name string

Theodore J Torphy

1

1 reference

Europe PubMed Central

4 September 2017

Janet Allen

2

1 reference

Europe PubMed Central

4 September 2017

André M Cantin

3

1 reference

Europe PubMed Central

4 September 2017

Michael W Konstan

4

1 reference

Europe PubMed Central

4 September 2017

Frank J Accurso

5

1 reference

Europe PubMed Central

4 September 2017

Elizabeth Joseloff

6

1 reference

Europe PubMed Central

4 September 2017

Felix A Ratjen

7

1 reference

Europe PubMed Central

4 September 2017

Antiinflammatory Therapy Working Group

9

1 reference

Europe PubMed Central

4 September 2017

publication date

6 July 2015

1 reference

Europe PubMed Central

4 September 2017

Proceedings of the American Thoracic Society

1 reference

Europe PubMed Central

4 September 2017

12

1 reference

Europe PubMed Central

4 September 2017

9

1 reference

Europe PubMed Central

4 September 2017

1398-1406

1 reference

Europe PubMed Central

4 September 2017

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Anti-inflammatory therapies for cystic fibrosis-related lung disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Origins of cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Immune responses in cystic fibrosis: are they intrinsically defective?

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Effects of airway surface liquid pH on host defense in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Immunologic aspects of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Neutrophil cell death, activation and bacterial infection in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

The role of inflammation in the pathophysiology of CF lung disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Association of cystic fibrosis with abnormalities in fatty acid metabolism.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Lipoxins and new lipid mediators in the resolution of inflammation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Resolving the problem of persistence in the switch from acute to chronic inflammation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

PDE4 inhibitors: current status

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Phosphodiesterase-4 inhibitor therapy for lung diseases

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Lipoxins: endogenous regulators of inflammation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Lipoxins: resolutionary road

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Resolvins: natural agonists for resolution of pulmonary inflammation.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Novel proresolving aspirin-triggered DHA pathway

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Cannabinoid-based drugs as anti-inflammatory therapeutics

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Asthma in Hispanics. An 8-year update

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Is cystic fibrosis a TH17 disease?

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Intrinsic predisposition of naïve cystic fibrosis T cells to differentiate towards a Th17 phenotype

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

The Th17 pathway in cystic fibrosis lung disease.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Effect of IL-17A blockade with secukinumab in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Risk Factors for Bronchiectasis in Children with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201506-361OT

21 January 2018

Identifiers

10.1513/ANNALSATS.201506-361OT

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38543069&oldid=1766518709"